-
-
Overview
-
Sulfamethazine sodium, also known as sulfadimidine sodium, is a bacteriostatic heterocyclic sulfonamide antibiotic that was first synthesized from sulfanilamide at Temple University in Philadelphia by William Caldwell in 1942. Sulfamethazine has broad-spectrum antimicrobial activity effectively targeting bacteria causing bronchitis, prostatitis, and urinary tract infections. It is used in disposition and depletion studies of kinetics and to develop procedures used for quantification. Sulfamethazine is also an inducer of CYP3A4.
Sulfamathazine has been shown to suppress epigenetic silencing in arabidopsis by impairing folate synthesis.
Sulfamethazine blocks the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase. Sulfamethazine is a competitive inhibitor of bacterial para-aminobenzoic acid (PABA), which is required for bacterial synthesis of folic acid. It induces CYP3A4 expression and is acetylated by N-acetyltransferase.
Sulfamethazine is soluble in DMSO (56 mg/mL at 25° C), water (<1 mg/mL at 25° C), and ethanol (<1 mg/mL at 25° C).Please contact us at for specific academic pricing.
Background
Sulfonamides, like sulfamethazine sodium, inhibit the enzymatic conversion of pteridine and p-aminobenzoic acid (PABA) to dihydropteroic acid by competing with PABA for binding to dihydrofolate synthetase, an intermediate of tetrahydrofolic acid (THF) synthesis. THF is required for the synthesis of purines and dTMP and inhibition of its synthesis inhibits bacterial growth.
-
- Properties
- Applications
-
Overview